Netakimab clinical trials
How each study uses netakimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Netakimab
- 3
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses netakimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3SPH-BIOCAD (HK) LimitedNCT07008547Written as Netakimab
- Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3BiocadNCT06640517Written as Netakimab
- Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing SpondylitisCompletedPhase 3SPH-BIOCAD (HK) LimitedNCT07277179Written as Netakimab
Codes
What other systems call netakimab · ClinicalTrials.gg INT001688
- MeSH (NLM) C000718740netakimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D3IAG45DAKNETAKIMABConfirmed FDA, NLM
- NCI Thesaurus C175830NetakimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718740 | netakimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D3IAG45DAK | NETAKIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C175830 | Netakimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.